141 related articles for article (PubMed ID: 35067571)
1. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
3. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
Sanchez VA; Shuey MM; Dinh PC; Monahan PO; Fosså SD; Sesso HD; Dolan ME; Einhorn LH; Vaughn DJ; Martin NE; Feldman DR; Kroenke K; Fung C; Frisina RD; Travis LB
J Clin Oncol; 2023 Apr; 41(12):2211-2226. PubMed ID: 36626694
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
6. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
7. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
[TBL] [Abstract][Full Text] [Related]
8. Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?
Skalleberg J; Myhrum M; Småstuen MC; Osnes TA; Fosså SD; Bunne M
Acta Oncol; 2021 Apr; 60(4):426-433. PubMed ID: 33617403
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of and Characteristics Associated With Self-reported Good Hearing in a Population With Elevated Audiometric Thresholds.
Curti SA; Taylor EN; Su D; Spankovich C
JAMA Otolaryngol Head Neck Surg; 2019 Jul; 145(7):626-633. PubMed ID: 31169892
[TBL] [Abstract][Full Text] [Related]
10. Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
Funt SA; Knezevic A; Wilson K; Bromberg M; Budnick A; O'Connor KL; McHugh DJ; Larsen E; Bajorin DF; Motzer RJ; Tonorezos ES; Patil S; Feldman DR
Cancer; 2023 Dec; 129(24):3952-3961. PubMed ID: 37715631
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
12. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Self-reported Measures of Hearing With an Objective Audiometric Measure in Adults in the English Longitudinal Study of Ageing.
Tsimpida D; Kontopantelis E; Ashcroft D; Panagioti M
JAMA Netw Open; 2020 Aug; 3(8):e2015009. PubMed ID: 32852555
[TBL] [Abstract][Full Text] [Related]
14. Discrepancy between self-assessed hearing status and measured audiometric evaluation.
Kim SY; Kim HJ; Kim MS; Park B; Kim JH; Choi HG
PLoS One; 2017; 12(8):e0182718. PubMed ID: 28792529
[TBL] [Abstract][Full Text] [Related]
15. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
16. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
18. Discrepancies between self-reported hearing difficulty and hearing loss diagnosed by audiometry: prevalence and associated factors in a national survey.
Choi JE; Moon IJ; Baek SY; Kim SW; Cho YS
BMJ Open; 2019 May; 9(4):e022440. PubMed ID: 31048419
[TBL] [Abstract][Full Text] [Related]
19. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
ArdeshirRouhaniFard S; Dinh PC; Monahan PO; Fossa SD; Huddart R; Fung C; Song Y; Feldman DR; Hamilton RJ; Vaughn DJ; Martin NE; Kollmannsberger C; Einhorn L; Kroenke K; Travis LB
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1129-1138. PubMed ID: 33849970
[TBL] [Abstract][Full Text] [Related]
20. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
